{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:20:44Z","timestamp":1785388844616,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06096-x","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:19:24Z","timestamp":1732245564000},"page":"5241-5248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry"],"prefix":"10.1007","volume":"103","author":[{"given":"S.","family":"Mathur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Christou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Delage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Elemary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DS.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MM.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA.","family":"Lother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mozessohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nevill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sabloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"St-Hilaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Storring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AE.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zarychanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"3","key":"6096_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223\u2013232. https:\/\/doi.org\/10.1016\/S1470-2045(09)70003-8","journal-title":"Lancet Oncol"},{"issue":"10","key":"6096_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","volume":"58","author":"JA Trubiano","year":"2017","unstructured":"Trubiano JA, Dickinson M, Thursky KA et al (2017) Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leuk Lymphoma 58(10):2379\u20132386. https:\/\/doi.org\/10.1080\/10428194.2017.1295141","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6096_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","volume":"97","author":"A Toma","year":"2012","unstructured":"Toma A, Fenaux P, Dreyfus F, Cordonnier C (2012) Infections in myelodysplastic syndromes. Haematologica 97(10):1459\u20131470. https:\/\/doi.org\/10.3324\/haematol.2012.063420","journal-title":"Haematologica"},{"key":"6096_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/tid.12130","volume":"15","author":"LR Sullivan","year":"2013","unstructured":"Sullivan LR, Sekeres MA, Shrestha NK et al (2013) Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Disease 15:652\u2013657. https:\/\/doi.org\/10.1111\/tid.12130","journal-title":"Transpl Infect Disease"},{"key":"6096_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/joh.23368","volume":"88","author":"D Merkel","year":"2013","unstructured":"Merkel D, Filanovsky K, Gafter-gvili A et al (2013) Predicting infections in high-risk patients with myelodysplastic syndrome\/ acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 88:130\u2013134. https:\/\/doi.org\/10.1002\/joh.23368","journal-title":"Am J Hematol"},{"issue":"1","key":"6096_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","volume":"14","author":"JF Falantes","year":"2014","unstructured":"Falantes JF, Calder\u00f3n C, M\u00e1rquez-malaver FJ et al (2014) Patterns of infection in patients with myelodysplastic syndromes and Acute Myeloid Leukemia receiving Azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 14(1):80\u201386. https:\/\/doi.org\/10.1016\/j.clml.2013.09.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6096_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/myc.12500","volume":"59","author":"H Pomares","year":"2016","unstructured":"Pomares H, Montserrat A, Sureda A, Duarte RF (2016) Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses 59:516\u2013519. https:\/\/doi.org\/10.1111\/myc.12500","journal-title":"Mycoses"},{"key":"6096_CR8","doi-asserted-by":"publisher","unstructured":"Johnson S, Lavergne V, Skinner AM et al (2021) Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. 73:755\u2013757. https:\/\/doi.org\/10.1093\/cid\/ciab718","DOI":"10.1093\/cid\/ciab718"},{"key":"6096_CR9","doi-asserted-by":"publisher","unstructured":"Goldberg SL, Chen E, Corral M, Guo A, Mody-patel N, Pecora AL (2010) Incidence and Clinical Complications of Myelodysplastic Syndromes among United States Medicare Beneficiaries. 28(17):2847\u20132852. https:\/\/doi.org\/10.1200\/JCO.2009.25.2395","DOI":"10.1200\/JCO.2009.25.2395"},{"key":"6096_CR10","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/cncr.24984","volume":"116","author":"F Dayyani","year":"2010","unstructured":"Dayyani F, Conley AP, Strom SS, Stevenson W (2010) Cause of death in patients with Lower-Risk Myelodysplastic Syndrome. Cancer 116:2174\u20132179. https:\/\/doi.org\/10.1002\/cncr.24984","journal-title":"Cancer"},{"issue":"4","key":"6096_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.leukres.2010.07.006","volume":"35","author":"Jhwan Lee","year":"2011","unstructured":"Lee Jhwan, Lee Khyung, Lee Jhee et al (2011) Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res 35(4):499\u2013503. https:\/\/doi.org\/10.1016\/j.leukres.2010.07.006","journal-title":"Leuk Res"},{"issue":"1","key":"6096_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjh.14033","volume":"174","author":"R Buckstein","year":"2016","unstructured":"Buckstein R, Wells RA, Zhu N et al (2016) Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol 174(1):88\u2013101. https:\/\/doi.org\/10.1111\/bjh.14033","journal-title":"Br J Haematol"},{"issue":"2","key":"6096_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3324\/haematol.2022.280723","volume":"108","author":"J Teichman","year":"2023","unstructured":"Teichman J, Geddes M, Zhu N et al (2023) High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes. Haematologica 108(2):532\u2013542. https:\/\/doi.org\/10.3324\/haematol.2022.280723","journal-title":"Haematologica"},{"key":"6096_CR14","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1038\/s41375-020-01026-y","volume":"34","author":"B Wan","year":"2020","unstructured":"Wan B, Nazha A, Starkman R et al (2020) Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia 34:3434","journal-title":"Leukemia"},{"issue":"5","key":"6096_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337\u2013343","journal-title":"Ann Med"},{"issue":"9","key":"6096_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.clml.2018.05.017","volume":"18","author":"L Shargian-Alon","year":"2018","unstructured":"Shargian-Alon L, Gurion R, Raanani P, Yahav D, Gafter-Gvili A (2018) Hypomethylating agents-associated infections\u2014systematic review and Meta-analysis of Randomized controlled trials. Clin Lymphoma Myeloma Leuk 18(9):603\u2013610e1. https:\/\/doi.org\/10.1016\/j.clml.2018.05.017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6096_CR17","doi-asserted-by":"publisher","unstructured":"Vilorio-Marqu\u00e9s L, Casta\u00f1\u00f3n Fern\u00e1ndez C, Mora E et al (2022) Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. Ther Adv Hematol 13. https:\/\/doi.org\/10.1177\/20406207221127547","DOI":"10.1177\/20406207221127547"},{"key":"6096_CR18","doi-asserted-by":"publisher","unstructured":"Kirkizlar TA, Kirkizlar O, Demirci U et al (2023) Incidence and predisposing factors of infection in patients treated with hypomethylating agents. Leuk Res 127. https:\/\/doi.org\/10.1016\/j.leukres.2023.107043","DOI":"10.1016\/j.leukres.2023.107043"},{"issue":"7","key":"6096_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00277-017-3001-2","volume":"96","author":"A Schuck","year":"2017","unstructured":"Schuck A, Goette MC, Neukirchen J et al (2017) A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Ann Hematol 96(7):1097\u20131104. https:\/\/doi.org\/10.1007\/s00277-017-3001-2","journal-title":"Ann Hematol"},{"issue":"24","key":"6096_CR20","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"LR Silverman","year":"2006","unstructured":"Silverman LR, Mckenzie DR, Peterson BL et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24(24):3895\u20133903. https:\/\/doi.org\/10.1200\/JCO.2005.05.4346","journal-title":"J Clin Oncol"},{"issue":"2","key":"6096_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Th\u00e9pot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117(2):403\u2013411","journal-title":"Blood"},{"key":"6096_CR22","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1182\/blood.V110.11.2858.2858","volume":"110","author":"N Jain","year":"2007","unstructured":"Jain N, Mattiuzzi G, Cortes J, Cassat J (2007) Benefit of Anti-infectious Prophylaxis in patients with Acute myeloid leukemia or high-risk myelodysplastic syndrome receiving Frontline targeted therapy. Blood 110:2858","journal-title":"Blood"},{"issue":"11","key":"6096_CR23","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1182\/blood.V108.11.4483.4483","volume":"108","author":"G Matiuzzi","year":"2006","unstructured":"Matiuzzi G, Cortes J, Faderi S, Cabanillas M (2006) Patients with Acute Myelogenous Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) treated with targeted therapy May Benefit from Prophylactic measures against infections. Blood 108(11):4483","journal-title":"Blood"},{"issue":"20","key":"6096_CR24","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06096-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06096-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06096-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:14:16Z","timestamp":1735866856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06096-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6096"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06096-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Manitoba Research Ethics Board. All patients provided written consent to be enrolled in the Canadian MDS Registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}